VR Adviser’s Xenon Pharmaceuticals XENE Stock Holding History

VR Adviser’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-30,000	Closed	-$913K	–	34
2022 Q2	$913K	Buy	+30,000	New	+$907K	0.18%	27

Other funds holding XENE

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

VR Adviser's XENE Position: Q3 2022 in Review

VR Adviser sold out of Xenon Pharmaceuticals (XENE) in Q3 2022, closing a stake of 30,000 shares — an estimated $913K sold.

VR Adviser first reported a position in XENE in Q2 2022 and held it in 1 quarter. The position peaked at $913K in Q2 2022. 154 funds tracked by Wall St. Rank hold XENE as of Q3 2022.

VR Adviser reported no remaining Xenon Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
VR Adviser sold 30,000 Xenon Pharmaceuticals shares in Q3 2022, an estimated $913K.
VR Adviser first reported a position in Xenon Pharmaceuticals in Q2 2022 and held it in 1 quarter.
VR Adviser's Xenon Pharmaceuticals position peaked at $913K in Q2 2022.
154 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2022.

Based on VR Adviser's 13F filing for Q3 2022, filed 14 Nov 2022.